Evidence map›Paper›PMID 42122242›Full record

ReviewCancers2026

Hodgkin Reed-Sternberg Cells of Classic Hodgkin Lymphoma: Morphology, Phenotype, Genotype, and Cell of Origin.

Annunziata Gloghini, Daniele Lorenzini, Chiara Costanza Volpi, Desirè Viola Trupia, Giancarlo Pruneri

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Annunziata GloghiniDepartment of Advanced Diagnostics, Fondazione IRCCS, Istituto Tumori Milano, 20133 Milan, Italy.ORCID 0000-0002-7226-1942
Daniele LorenziniDepartment of Advanced Diagnostics, Fondazione IRCCS, Istituto Tumori Milano, 20133 Milan, Italy.ORCID 0000-0002-1425-3354
Chiara Costanza VolpiDepartment of Advanced Diagnostics, Fondazione IRCCS, Istituto Tumori Milano, 20133 Milan, Italy.ORCID 0000-0002-8306-6851
Desirè Viola TrupiaDepartment of Advanced Diagnostics, Fondazione IRCCS, Istituto Tumori Milano, 20133 Milan, Italy.
Giancarlo PruneriDepartment of Advanced Diagnostics, Fondazione IRCCS, Istituto Tumori Milano, 20133 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classic Hodgkin lymphoma (cHL) is a distinctive B-cell malignancy defined by the presence of scarce but pathobiologically dominant Hodgkin Reed-Sternberg (HRS) cells within an inflammatory tumor microenvironment (TME). Although representing less than 10% of total tumor cellularity, HRS cells shape the TME by recruiting and functionally polarizing immune and stromal elements through cytokine- and chemokine-mediated signaling. Morphologically, HRS cells are large, atypical, often binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, giving rise to the classic "owl's eye" appearance. Distinct morphological variants-including lacunar, mummified, mononuclear, and anaplastic forms-contribute to the histopathologic diversity across cHL subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted disease. The immunophenotype of HRS cells is equally characteristic, with strong and uniform CD30 expression, frequent CD15 positivity, reduced expression of B-cell markers (CD20, CD79A/B), and partial retention of PAX5, reflecting profound lineage dysregulation. Aberrant expression of activation markers and immune-evasion molecules, including PD-L1 driven by recurrent 9p24.1 amplification, underscores their capacity for immune escape. Genetically, HRS cells display alterations affecting

Indexed as

cell of originclassic Hodgkin lymphomagenotypeHodgkin Reed-Sternberg cellsmorphologyphenotype

Identifiers

PMID42122242
PMCPMC13162904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.